Big pharma firms have paused nearly £2bn in UK investments this year
The article reports that major pharmaceutical companies have paused or abandoned nearly £2 billion in planned investments in the UK this year. This includes MSD's decision to scrap a £1 billion research center in London and AstraZeneca's halt on a £200 million expansion of its facilities in Cambridge. The moves have been attributed to the government's plans for the life science sector, a key part of the UK economy, being thrown into disarray. The article suggests these decisions may lead to job losses and could negatively impact patient care. The article also notes that these developments come as the UK government prepares to discuss drug pricing with US President Donald Trump.
Source: For the complete article, please visit the original source link below.
